The molecular mechanisms leading to DCM in laminopathies are largely unknown, but expected to be diverse, in keeping with the multiple functions of LMNA in cardiac myocytes. 13, 14 Alterations in signaling pathways, including MAPK (mitogen-activated protein kinase), AKT (protein kinase B), NOTCH (neurogenic locus notch homolog protein), and WNT (wingless-related integration) pathways, have been implicated along with changes in mechanotransduction and the linker of nucleoskeleton and cytoskeleton complex. 7, 13, 15, 16 Dysregulated gene expression, proposed by Hutchinson over a decade ago, 14 has emerged as the prevailing mechanism to explain phenotypic plasticity of the LMNA mutations. The hypothesis is based on the known interactions of LMNA, directly or indirectly through other nuclear lamina proteins, with chromatin in >1000 genomic regions. [17] [18] [19] The LMNA-associated domains (LADs), with an average length of ≈500 kilobase pairs, are predominantly located in the heterochromatin and generally gene-poor regions, but they also involve gene-rich and the regulatory loci. 18, [20] [21] [22] Consequently, LMNA is expected to influence expression of a diverse array of genes involved in various biological processes, which are likely to be pertinent to the pathogenesis of the phenotypes in laminopathies. 17, 18 Thus, the purpose of the study was to identify the differentially expressed genes and their upstream (transcriptional) regulators and to determine potential beneficial effects of targeting of the main dysregulated pathway in LMNA deficiency. The objectives are to gain new insights into the molecular pathogenesis of cardiac phenotypes in laminopathies and identify new therapeutic targets.
Methods
The data, methods used in the analysis, and materials used to conduct the research will be made available to any researcher for purposes of reproducing the results or replicating the procedure. The transcriptomic data will be deposited in NCBI GEO (National Center for Biotechnology Information Gene Expression Omnibus) Profile, which will maintain the data indefinitely A detailed Methods section has been provided as Online Data Supplement. The studies conformed to the Guide for the Care and Use of Laboratory Animals published by the US National Institutes of Health and were approved by the Animal Care and Use Committee and the Biological Safety Committee of the University of Texas Health Science Center-Houston.
Lmna −/− and Wild-Type (WT) Littermates
The phenotype in the Lmna −/− mice has been published. 23, 24 Oligonucleotide primers used in polymerase chain reaction (PCR) reactions are listed in Online Table I .
Gross Morphology and Survival
Body weight (BW) was recorded weekly, and heart weight/BW ratio was calculated in age-and sex-matched mice. Survival was analyzed by constructing Kaplan-Meier survival plots.
Echocardiography
Cardiac size and function were assessed in age-and sex-matched mice by 2-dimensional, M mode, and Doppler echocardiography 
Novelty and Significance
What Is Known?
• Mutations in LMNA gene cause over a dozen distinct phenotypes, including dilated cardiomyopathy.
• LMNA is among the common causal genes for hereditary dilated cardiomyopathy.
• The molecular pathogenesis of dilated cardiomyopathy caused by the LMNA mutations is largely unknown and seems to involve several signaling pathways, including MAPK (mitogen-activated protein kinase), NOTCH (neurogenic locus notch homolog protein), and canonical Wnt (wingless-related integration).
• Genetic deletion of the Lmna gene in mice leads to several cardiac dysfunction and premature death by 4 to 8 weeks of age.
What New Information Does This Article Contribute?
• We sequenced ribosome-depleted whole-heart transcripts (RNA sequencing) in 2-week-old Lmna −/− mice, before the onset of cardiac dysfunction, and their wild-type littermates.
• We identified ≈1000 differentially expressed genes, the majority of which were upregulated in the Lmna −/− hearts.
• Network analysis of differentially expressed genes led to identification of >2 dozen deranged upstream regulators of gene expression.
• Forkhead box O (FOXO) transcription factors were among the most activated upstream transcriptional regulators, a finding that was validated by multiple methods.
• Knockdown of FOXO1 and FOXO3 in the heart using recombinant adeno-associated viruses, expressing a sequence-specific short hairpin RNA, attenuated apoptosis and nearly doubled the survival time in the Lmna −/− mice.
The findings of the present study point to multiplicity of the pathogenic pathways dysregulated in the heart in LMNA deficiency, including activation of FOXO 1 and 3 transcription factors. The findings also identify FOXO 1 and 3 as potential therapeutic targets in dilated cardiomyopathy caused by the LMNA mutations. Furthermore, the findings highlight the shortcomings of targeting of a single pathogenic pathway in fully rescuing the phenotype. Therefore, targeting of multiple pathogenic pathways might be required for superior therapeutic achievements in heart failure caused by the LMNA mutations. March 2, 2018 using a Vevo 1100 ultrasound imaging system equipped with a 22-to 55-MHz MicroScan transducer (MS550D; FUJIFILM VisualSonics Inc, Toronto, ON, Canada), as published.
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Isolation of Adult Cardiac Myocytes
Adult cardiac myocytes were isolated as published. 26, 29 In brief, the excised heart was perfused with a digestion buffer containing collagenase II, and the perfusion was continued until complete softening of the myocardium. The cells were dissociated from the digested hearts by gentle pipetting and were placed in a buffer containing 10% calf serum and 12.5 μmol/L CaCl 2 to stop the reaction. Cells were then filtered through a 100-μm nylon mesh, and myocytes were left to sediment by gravity in the presence of 2 mmol/L ATP and pelleted by centrifugation at 20g. Myocytes were reintroduced to calcium in stepwise concentrations of 100, 400, and 900 μm and added to the stop buffer at 2 mmol/L ATP. The isolated myocytes were resuspended in a plating media containing antibiotics, calf serum, and ATP. The isolated myocytes were placed on laminin-coated cover glasses in a 2% CO 2 incubator at 37°C or were immediately frozen.
Isolation of Neonatal Mouse Ventricular Myocytes and Transduction With Adenoviruses
Cardiac cells were isolated from 1-to 2-day old WT mice by enzymatic dispersion with collagenase and pacreatin. Neonatal mouse cardiac myocytes were separated from the rest of the cells by differential attachment and grown on chamber slides. On day 2, cells were infected with recombinant adenoviruses expressing a constitutively active form of forkhead box O (FOXO; Ad-FOXO AAA ) or a vector virus alone (Vector Biolabs, no. 1025 and no. 1300) for 48 hours with a multiplicity of infection of 20. 30, 31 Neonatal mouse cardiac myocytes were treated for superoxide mitochondrial production detection by MitoSOX or were fixed for detection of apoptosis.
Histology
Fibrosis was assessed on staining of thin myocardial sections with Masson trichrome and Sirius Red, as described. 26, 29, 32 Collagen volume fraction was calculated as published.
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Detection of Apoptosis
Apoptosis was detected by nick-end labeling of DNA with the TUNEL (terminal deoxynucleotidyl transferase dUTP nick-end labeling) assay using In Situ Cell Death Detection Kit (Roche catalogue no. 11684795910 and 12156792910) per manufacturer instructions and quantification of the transcript levels of genes involved in apoptosis, as published. 26, 29, 33 Quantitative Real-Time PCR Total RNA was extracted from myocardial tissue or from isolated cardiac myocytes using the Qiagen miRNeasy Mini Kit (catalogue no. 217006). 25, 28 Taqman probes and SYBR Green primers are detailed in Online Table I .
Immunoblotting of Total and Cellular Protein Fractions
Expression levels of the proteins of interest in mouse heart samples and isolated cardiac myocytes were detected and quantified by immunoblotting, as described. 25, 26, 28 Nuclear and cytosolic proteins were extracted using a commercial kit (ProteoExtract, Calbiochem, catalogue no. 539790) and probes with the specific antibodies against proteins of interest. 34 Immunofluoresences were performed on thin myocardial sections as published. 25, 26, 29 
RNA Sequencing
RNA sequencing was performed in the whole-heart ribosome-depleted RNA extracts from the 2-week-old WT and Lmna −/− mice on an Illumina platform, as published with minor modifications. 25, 28 In brief, ribosome-depleted cardiac RNA samples were analyzed for integrity on an Agilent Bioanalyser RNA chip. Samples with high integrity index were used to prepare sequencing library using the Illumina TruSeq stranded total RNA library preparation kit. The samples were sequenced on the Illumina HiSeq 4000 instrument using the pairedend sequencing reagents to generate 100 base pair runs.
Raw RNA sequencing reads were mapped to the mouse reference genome build 10 (UCSC mm10/GRCm38) by Tophat2. 35 Gene expression was assessed using Cufflinks2 and the GENCODE gene model. 35, 36 Only transcripts that exceeded 1 fragments per kilobase of transcript per million mapped fragments in at least 1 sample were included in the analyses. Differentially expressed transcripts (DETs) were identified using the edgeR analysis package in R statistical program with the significance level set at q<0.05 and the fold change at >1. 25 . Quality control and data visualization were assessed by principal components analysis and hierarchical clustering in R. GENE-E software (http://www.broadinstitute.org/cancer/ software/GENE-E) was used to generate the heat maps from the raw fragments per kilobase of transcript per million mapped fragments values, and the Graph Pad Prism was used to generate the volcano plots. Enriched upstream regulators and transcription factor (TF)-binding sequence motifs were inferred using gene set enrichment analysis (GSEA; version 2.2.3, http://software.broadinstitute. org/gsea/), TF-binding motifs TRANSFAC, 37 Molecular Signature Database, [38] [39] [40] and the Ingenuity Pathway Analysis (Qiagen). Gene ontology analyses were conducted using ConsensusPathDB (release MM9-http://cpdb.molgen.mpg.de/MCPDB), [41] [42] [43] and gene ontology terms were gathered according to their similarities using REVIGO (http://revigo.irb.hr/). 44 Circos plot was generated in R using the GO-Chord option.
AAV9-Mediated In Vivo Suppression of FOXO TFs in the Heart
A previously validated short hairpin RNA (shRNA) that targets FOXO1 and FOXO3 45, 46 was cloned into adeno-associated virus serotype 9 (AAV9) vectors downstream to a U6 promoter (VectoBiolab). Control AAV9 vectors contained either a GFP (green fluorescence protein) or a scrambled shRNA expression cassette. Sequence of the shRNA against FOXO1 and 3 and scrambled shRNA are presented in Online Table I .
To knockdown expression of FOXO1 and FOXO3 in the heart, recombinant AAV9 constructs at a titer of 0.5×10 11 vector genomes per gram of BW (vg/g) were injected subcutaneously into neonatal mice, sequentially at P2, P4, and P6 postnatal days, delivering a total of 1.5×10 11 vg/g to each mouse. Control AAV9 vectors were injected at the same dosage and time points. The early time points were chosen to allow sufficient time for gene expression before the onset of cardiac phenotypes in the Lmna −/− mice. 23, 24 Serial injections before complete immune competency are expected to enhance transduction efficiency by targeting the newly formed cardiac myocytes. 47 The viral titer was chosen to induce an efficient transduction of cardiac myocytes without toxicity.
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Cytokines Measurement
Cytokine and chemokine levels in the heart of 2-week-old WT and Lmna −/− mice were measured using the Milliplex MAP Mouse Cytokine/Chemokine 32-plex assay (Millipore) according to manufacturer's protocol (MCYTMAG-70K-PX32).
Mitochondrial Electron Chain Transport Activity
Enzymatic activity of each of the complexes of mitochondrial electron transport chain (ETC) was assessed in the heart of 2-week-old WT and Lmna −/− mice by adding the specific substrates to cardiac homogenates, as published. 51 All activities were calculated as nmoles/ min per milligram protein, normalized to citrate synthase activity, and expressed as a percentage of WT activity.
Mitochondrial ETC Complexes Assembly Immunoblotting
ETC complexes assembly was assessed by immunoblotting of specific subunit of each of the 5 ETC complexes using the Total OXPHOS Rodent WB Antibody Cocktail (Abcam, #ab110413) per manufacturer's instruction.
Mitochondrial Superoxide Anion Production Detection by MitoSOX
Mouse neonatal ventricular myocytes were incubated with Red MitoSOX according to manufacturer's instructions.
Statistical Analyses
Data that followed a Gaussian distribution pattern were presented as mean±SEM and were compared by t test and 1-way ANOVA. Otherwise, data were presented as the median values and compared by Kruskall-Wallis test, as were the categorical data. Survival rates were analyzed by constructing Kaplan-Meier survival plots and comparing the survival rate by log-rank (Mantel-Cox) test.
Results
Cardiac Phenotype in 2-Week-Old Lmna −/− Mice
To validate deletion of the Lmna gene, cardiac protein extracts from the WT and Lmna −/− mice were probed for the expression of the LMNA protein using an anti-LMNA antibody. As expected, expression of the LMNA protein was not detected in the heart of the Lmna Given that BW is a major determinant of cardiac size, including echocardiographic indices of left ventricular dimension, these indices were corrected for the BW. Accordingly, heart weight/BW ratio was not significantly different between Lmna −/− and WT mice (Online Figure ID) . To detect early transcriptomic changes that precede cardiac dysfunction, and therefore, to reduce the confounding changes, cardiac function was analyzed in 2-week-old Lmna −/− and WT mice by echocardiography. Consistent with the previous data, there were no differences in the echocardiographic indices of cardiac size and function between 2-week-old Lmna −/− and WT mice with the exception of the mean left ventricular end-diastolic diameter corrected for BW, which was slightly enlarged in the Lmna −/− mice (by 0.05 mm/g; P=0.032) while left ventricular fractional shortening was normal (Online Table II) . 23, 24, 52 Histological examinations showed no discernible cardiac fibrosis in the Lmna −/− mice at 2 weeks of age (Online Figure  IE and IF). In accord with the histological findings, levels of Col1a1, Col1a2, and Tgfb1 transcripts, markers of fibrosis, as assessed by quantitative PCR (qPCR), were unchanged in the hearts of 2-week-old Lmna −/− mice (Online Figure IG) .
Differentially Expressed Cardiac Transcripts in 2-Week-Old Lmna −/− Mice
Given the absence of discernible cardiac dysfunction in the Lmna −/− mice, RNA sequencing (RNA-Seq) was performed in the ribosome-depleted cardiac transcripts isolated from the hearts of 2-week-old WT and Lmna −/− mice (whole-heart ribosome-depleted RNA). Of the 809 genes that were dysregulated in the hearts of 2-week-old Lmna −/− , as compared with the WT mice, 233 were downregulated and 576 upregulated. Volcano plots and heat maps of the DETs are shown in Figure 1A and 1B.
To corroborate the DETs identified by RNA-Seq, transcript levels of randomly selected 20 dysregulated genes, showing at least a 2-fold or higher change (q<0.05), were analyzed by qPCR in the whole hearts in an independent set of WT and Lmna −/− mouse hearts. As shown in Figure 1C , the findings corroborated the RNA-Seq findings.
Dysregulated Upstream Transcriptional Regulators and Enriched TF-Binding Sites in the DETs in the Lmna −/− Hearts
To identify the dysregulated upstream transcriptional regulators in the Lmna −/− hearts, DETs were analyzed against the Molecular Signature Database to identify over-representation of the binding sites of the TFs in the promoter regions of the differentially expressed genes. The consensus binding motif for FOXO TFs (TTGTTT) was over-represented in the upregulated genes while the motif for E2 factors was the most over-represented in genes whose transcript levels were reduced ( Figure 1D and 1E ). In addition, motifs for the NFAT (nuclear factor of activated T-cells), AP1 (activator protein 1), and E12 TFs showed significant enrichment in the Lmna −/− hearts. Nevertheless, FOXO TFs had by far the most dysregulated targets ( Figure 1D ). Detailed results are provided in Online Table III .
Ingenuity pathway analysis of the DETs also identified FOXO3 among the top transcriptional regulators in the Lmna ; Online Table IV) . A total of 145 FOXO target genes were dysregulated in the heart of Lmna −/− mice, of which 128 were upregulated, and only 19 were downregulated ( Figure 2A ). The magnitude of the differential expression of FOXO TF targets is illustrated in the heat map ( Figure 2B ). Quantitative PCR analysis also showed increased transcript levels of Foxo3 in the Lmna −/− mouse hearts ( Figure 2C ). The FOXO family of TFs share TTGTTT as their common binding site motif. Therefore, the analysis of the differentially expressed genes does not enable distinction among the specific dysregulated FOXO TFs. Therefore, network analysis by ingenuity pathway analysis showed dysregulated transcript levels of several FOXO TF targets, which were shared among the 3 common FOXO TFs expressed in the heart ( Figure 2D ). 53 To further corroborate activation of the FOXO TFs in the hearts in the Lmna −/− mice, transcript levels of a selected number of FOXO TF targets were analyzed by qPCR. The findings were notable for increased levels in the Lmna −/− as opposed to the WT hearts ( Figure 2E ).
Increased Nuclear Localization of FOXO1 and 3 in the Lmna −/− Hearts
To further corroborate evidence for the activation of FOXO TFs, levels of FOXO1, 3, and 4 transcripts and proteins were determined by qPCR, immunoblotting, and immunofluorescence, respectively. Transcript levels of Foxo3, the most abundant FOXO TF in the heart, but not Foxo1 and Foxo4, were increased significantly in the heart, likely reflecting autoregulation ( Figure 2C ). Immunoblotting of myocardial nuclear protein subfraction showed increased levels of FOXO1 and FOXO3 by 1.4±0.1-fold (n=5; P=0.035) and 1.8±0.1-fold (n=6; P=0.014 versus WT), respectively, in the Lmna −/− as compared with WT mouse hearts, whereas FOXO4 levels were unchanged ( Figure 3A and 3B). Levels of FOXO3 in the cytoplasmic protein fraction were unchanged while those of FOXO1 were reduced by 46.0±3.9% (n=5; P=0.002 versus WT; Figure 3C and 3D). Levels of FOXO1 in the total protein extracts were increased 1.6±0.2-fold (n=8-9; P=0.0007) while FOXO3 and FOXO4 levels were unchanged ( Figure 3E and 3F) . Finally, because FOXO TFs are inactivated on phosphorylation at threonine residues 24 and 32 March 2, 2018 (Thr 24/32 ), pFOXO levels were determined in myocardial protein extracts using an antibody that recognizes phospho-FOXO1, 3, and 4 proteins. As shown, pFOXO1 and 3 levels were reduced by 63.4±2.6% (n=4; P=0.028 versus WT; Figure 3G and 3H) . Consequently, the relative levels of active to inactive FOXO1 and 3 were increased in Lmna −/− as compared with control WT mouse hearts ( Figure 3I ). Finally, FOXO3 nuclear localization was analyzed by immunofluorescence costaining of thin myocardial sections for FOXO3 and actinin α 2, the latter as a marker for cardiac myocytes. The number of myocytes −/− and WT, comprised 576 upregulated and 233 downregulated transcripts (insert circles). B, Heat map of the DETs. Transcripts were ranked, according to their differential expression across genotypes, from the most upregulated genes to the most downregulated in Lmna −/− hearts. C, Quantitative polymerase chain reaction validation of RNA-Seq data for 20 DETs, including Lmna, the latter as a control. The transcripts were randomly selected for validation among those showing ≈2-fold or higher change in RNA-Seq data and were differentially expressed at a q value of 0.05. Gene expression in Lmna −/− after normalization is presented here as log 2 of fold change relative to the expression levels in WT mice *P<0.05, **P<0.01, ***P<0.001, ****P<0.0001. D and E, Enrichment of conserved cis-regulatory motifs in DETs. DETs were analyzed using gene set enrichment analysis and the Molecular Signature Database for enrichment of transcription factor (TF)-binding motifs by hypergeometric distribution. Top 10 over-represented TFs among the upregulated (D) and downregulated (E) TFs are presented. The number of the genes in the overlap is displayed by size of the ball on the graph along with the color coding indicated in the insert. Detailed analysis is provided in Online showing localization of FOXO3 in the nucleus was increased in the Lmna −/− mouse hearts as compared with WT (1.8±0.2-fold in Lmna −/− mouse heart versus WT hearts; n=3; P=0.006; Figure 3J and 3K). Collectively, the findings indicate activation of FOXO1 and FOXO3 TFs in the hearts of the Lmna −/− mice. To extend the findings on activation of FOXO TFs in the Lmna −/− mouse hearts to human hearts with DCM, publically available RNA-seq data from failing and nonfailing human hearts (GSE46224) without defined mutations were analyzed by GSEA for the TF-binding motif enrichment. As shown in Online Figure II , the TTGTTT motif was significantly enriched in the human heart samples from patients with DCM.
This finding corroborates activation of the FOXO TFs in the Lmna −/− mouse hearts.
Dysregulated Biological Processes
To identify the biological processes associated with the dysregulated transcriptional regulators, cardiac transcripts were analyzed by GSEA using the Molecular Signature Database. Genes involved in inflammation, hypoxia, and apoptosis were upregulated and those involved in oxidative phosphorylation, cell cycle progression, and adipogenesis were downregulated ( Figure 4A and 4B). Given that genes involved in the inflammatory responses were prominently depicted in the hearts of the Lmna −/− mice, GSEA plot and transcript levels of genes involved in the NFκB (nuclear factor kappa-light-chain-enhancer of activated B cells) pathway were analyzed along with the protein levels of selected cytokines, the later by ELISA. GSEA plots showed marked enrichment of the NFκB pathway ( Figure 4C ). Likewise, mRNA levels of several NFκB target genes were increased significantly ( Figure 4D ). Moreover, myocardial levels of several cytokines, including CXCL1 (C-X-C motif chemokine ligand 1), CCL2 (C-C motif chemokine ligand 2), IL6 (interleukin 6), CXCL10 (C-X-C motif chemokine ligand 10), LIF (leukemia inhibitory factor), and IL9 (interleukin 9), were increased in the Lmna −/− mouse hearts as compared with WT mouse hearts ( Figure 4E ).
To further characterize the potential impact of FOXO activation in the heart, biological pathways that are regulated by FOXO target genes were curated using gene ontology . Gene ontology analysis of FOXO target genes identified programmed cell death as the most activated biological pathway in the Lmna −/− mouse hearts ( Figure 5A ). Consistent with this finding, GSEA of whole transcriptome showed enrichment of genes involved in apoptosis ( Figure 5B ). Transcript levels of a subset of FOXO TFs target genes involved in apoptosis were also quantified by qPCR and found to be significantly increased in the Lmna −/− mouse hearts ( Figure 4C ). In contrast, transcript levels of antiapoptotic gene Bcl2 were unchanged. TUNEL assays performed on thin myocardial sections showed a 3.8±0.5-fold increase in the number of TUNEL-positive nuclei in 2-week-old Lmna −/− mouse hearts and wild-type (WT) mouse hearts (E and F). Corresponding quantitative data show increased levels of FOXO3 in the nuclear protein subfraction by 1.8±0.14-fold (B, n=6; P=0.014 vs WT). FOXO1 levels also showed a modest increase in the nuclear protein extracts in the Lmna −/− mouse heart (1.4±0.1-fold; P=0.035), whereas FOXO4 levels were unchanged (B). Level of FOXO1 in the cytoplasmic protein fraction was reduced by 46.0±3.9% (n=5; P=0.002 vs WT), whereas levels of FOXO3 and FOXO4 were unchanged (C). A modest increase in levels of FOXO1 protein in the total myocardial protein extract (1.6±0.2-fold vs WT; n=8-9; P=0.0007) was also noted. There were no significant differences in levels of FOXO3 and FOXO4 in the total myocardial protein extracts between the groups (E and F). G-H, Immunoblot of phospho-Thr 24, 32 -FOXO1 and 3 (pFOXO1/3), total FOXO1 and 3, and GAPDH, the latter as a loading control. Levels of pFOXO1 and 3 were reduced by 63.4±2.6% in the Lmna −/− mouse hearts (n=4; P=0.028 vs WT; G and H). Conversely, the estimated active to inactive FOXO1 and 3 levels (total FOXO1/3-pFOXO1/3) were increased by 2.76±0.62-fold in Lmna −/− mouse hearts (P=0.038 vs WT; I). J and K, Representative immunofluorescence staining of FOXO3 and α-actinin (ACTN2), a myocyte marker, on thin myocardial section showing increased nuclear localization of FOXO3 in cardiac myocytes in the Lmna −/− mouse hearts compared with the WT (n=3; scale bar is 20 μm; J). Corresponding quantitative data, based on analysis of a minimum of 21 820 nuclei per group, are shown in K (0.26±0.02% vs 0.14±0.01% myocytes in the Lmna −/− and WT mouse hearts, respectively; P=0.006). *P<0.05, **P<0.01, ***P<0.001, ****P<0.0001.
(n=4 mice per group; P=0.002; Figure 5D and 5E). Finally, adenoviral-mediated expression of a constitutive active form of FOXO3 (Ad-FOXO3 AAA ) in neonatal mouse ventricular myocytes was associated with an increased number of TUNEL-positive nuclei (3.1±0.1-fold versus control vector; P<0.0001; Figure 5F and 5G). Altogether, the findings indicate a deleterious role for overactivation of FOXO TFs in the hearts of the Lmna −/− mice. Oxidative phosphorylation was the most suppressed biological function in the Lmna −/− mouse hearts ( Figure 4B ). Its suppression was demonstrated by GSEA, quantification of the transcript levels of selected mitochondrial genes, and determination of mitochondrial ETC activity (Online Figure III) . Complex I enzymatic activity was decreased by 37.0±7.8% (n=4; P=0.021 versus WT) and the transcript levels of the corresponding genes involved in complex I were also reduced (Online Figure III) . Likewise, suppression of the cell cycle regulatory pathways, namely E2 factor targets and G2M checkpoint, were confirmed in the Lmna −/− mouse hearts by GSEA along with quantification of transcript levels of selected genes in the pathways (Online Figure III) .
Suppression of FOXO TFs in the Lmna −/− Hearts
To establish the pathogenic role of activation of FOXO TFs in cardiac phenotypes in the Lmna −/− mice, recombinant AAV9 constructs were generated to target FOXO1 and 3 on expression of an established sequence-specific shRNA (AAV9-Foxo shRNA ). 45, 46 A prelude to AAV9-mediated gene targeting, which predominantly transduces cardiac myocytes, 54, 55 is evidence of activation of FOXO TFs in cardiac myocytes. Accordingly, cardiac myocytes were isolated from the WT and Lmna −/− mouse hearts and analyzed for the transcript levels of 15 randomly selected FOXO TF targets by qPCR. The results ( Figure 6A ) showed increased transcript levels of FOXO TF target genes in cardiac myocytes isolated from the Lmna −/− mouse hearts, indicating activation of the FOXO TFs in the Lmna −/− cardiac myocytes. shRNA were injected at P2, P4, and P6 days at a total 1.5×10 11 vg/g particles subcutaneously, followed by testing for knockdown of FOXO1 and FOXO3 TF at 2 weeks and phenotypic characterization at 4 weeks of age ( Figure 6B ).
Treatment with the control AAV9 constructs (AAV9-Gfp and AAV9-scrambled shRNA ) had no discernible effect on the survival rate (Online Figure IV) . Therefore, in the subsequent studies, AAV9-scrambled shRNA construct was used as a control group. Administration of AAV9-Foxo shRNA reduced Foxo3 transcript levels by 53.7±10% (P=0.026 compared with noninjected Lmna −/− mouse heart), which were increased in the Lmna −/− mouse hearts, effectively normalizing the levels (comparable to WT). Likewise, transcript levels of Foxo1 and Foxo4 were reduced significantly in the AAV9-Foxo shRNA group as compared with noninjected Lmna −/− mice (37.8±12%, P=0.017, and 37.4±18%, P=0.024, respectively, Figure 6C) . At the protein level, the most remarkable finding was reduced levels of FOXO3 on delivery of AAV9-Foxo shRNA construct, which was reduced by 61.6±4.5% compared with noninjected Lmna −/− mice (n=3; P=0.024; Figure 6D and 6E). Likewise, levels of FOXO1 protein were also reduced (49.5±13.9%; P=0.006 versus noninjected Lmna −/− mice) and were comparable to those in the WT mice while levels of FOXO4 were unchanged ( Figure 6D and 6E) . To further support effective knockdown of FOXO TF activities on administration of the AAV9-Foxo shRNA construct, transcript levels of several wellestablished FOXO TFs targets were quantified by qPCR. The results are remarkable for normalization of the transcript levels of FOXO TF targets in AAV9-Foxo shRNA group ( Figure 6F ).
Partial Phenotypic Rescue on Knockdown of FOXO TFs
To determine whether knockdown of FOXO TFs rescues the phenotype in the Lmna −/− mice, the effects of administration of the AAV9-Foxo shRNA construct on survival, cardiac function, and apoptosis were analyzed. Knockdown of FOXO TFs in the heart was associated with ≈2-fold prolongation of survival in the Lmna −/− mice as compared with untreated Lmna −/− mice or Lmna −/− mice injected with the control AAV9-Gfp or AAV9-scrambled shRNA vector constructs ( Figure 7A ; Online Figure IV) . Accordingly, the median survival time was increased from 29 days in the untreated Lmna −/− mice to 52 days in the AAV9-Foxo shRNA -treated mice. Given marked activation of the apoptotic pathways in the Lmna −/− mouse hearts, effects of knockdown of FOXO TFs on myocardial apoptosis were analyzed. Treatment with the AAV9-Foxo shRNA was associated with normalization of transcript levels of several genes involved in apoptosis, which are known to be FOXO TF targets ( Figure 7B ). Consistent with this finding, knockdown of FOXO TFs in the heart was associated with a significant reduction in the number of TUNEL-positive cells in the myocardium (58.2±18.6%; P=0.025 versus noninjected Lmna −/− mice; Figure 7C and 7D).
Administration of AAV9-Foxo shRNA did not have a significant effect on cardiac function (Online Table VI ). However, because of the presence of significant differences in the BW between the WT and Lmna −/− mice and BW dependence of the left ventricular dimensions, the effects on cardiac functions could not be reliably assessed. To determine whether knockdown of FOXO TFs had an effect on mitochondrial functions, selected parameters of mitochondrial functions were determined in the experimental groups (Online Figure V) . Integrity of the mitochondrial ETC complexes is reflected by the stable levels of known constituents of each complex, such as NDUFB8 for complex I and ATP5A for complex V. Therefore, levels of these labile protein constituents of mitochondrial ETC were quantified by immunblotting. As shown, only levels of NDUFB8 were reduced in the Lmna −/− mice (Online Figure V) . Administration of AAV9-FOXO shRNA did not rescue reduced levels of NDUFB8 and had no effect on other labile protein constituents of ETC, indicating a mechanism independent of FOXO TFs (Online Figure V) . Likewise, MitoSOX assay showed no significant effect on superoxide production in the neonatal mouse cardiac myocyte transduced with recombinant adenoviruses expressing constitutively active FOXO TFs (Online Figure V) . Moreover, no significant differences in the percent collagen volume fraction, indicative of interstitial fibrosis, were noted among the experimental groups (Online Figure VI) . Finally, myocardial architectures, as assessed by staining for actinin α 2 and JPH2 (junctophilin 2), were not affected in the Lmna −/− mice treated with adenoviral vector alone and after knockdown of FOXO TFs in the heart (Online Figure VII) .
Discussion
We identified ≈800 DETs in the hearts of Lmna −/− mice, which occurred in the absence of and before the onset of cardiac dysfunction. Dysregulated gene expression is in accord with the known role of LMNA in influencing chromatin structure through the LADs and regulation of gene expression. 17, 18, 20, 21 Most of the dysregulated transcripts were upregulated, which is consistent with the data suggesting that most genes at the LADs are transcriptionally silent or suppressed. 17, 19, 20 Because the changes occurred in the absence of and preceded discernible cardiac dysfunction, they are likely pathogenic and partly responsible for the cardiac phenotype, as opposed to being secondary to cardiac dysfunction. Bioinformatics analyses complemented with biological validations identified FOXO TFs as among the most activated transcriptional regulators in LMNA-deficient hearts. Knockdown of FOXO1 and FOXO3 using recombinant AAV9 expressing an established anti-FOXO1 and 3 shRNA indicated a pathogenic role for the FOXO TFs in induction of apoptosis and increased mortality in the Lmna −/− mice. Overall, these findings implicate FOXO TFs as an important transcriptional regulator in the pathogenesis of the cardiac phenotypes in laminopathies.
RNA-Seq was performed on ribosome-depleted wholeheart transcriptomes. Given the ubiquitous expression of LMNA in multiple cardiac cell types, DETs are expected to originate from multiple cell types. Likewise, cardiac phenotypes in laminopathies are expected to arise from pathogenic involvement of multiple cell types. In the present study, upregulation of FOXO TF targets were verified in the heart as well as in cardiac myocytes isolated from the Lmna −/− mouse hearts. In addition, partial rescue of cardiac phenotype on knockdown of FOXO TFs using recombinant AAV9, which predominantly target cardiac myocytes in the heart, 54,55 signifies the biological effects of activation of FOXO TFs in cardiac myocytes in lamin deficiency. Moreover, doubling of survival and marked reduction in apoptosis on targeting of FOXO TFs in cardiac myocytes emphasize the biological significance of this regulatory network in cardiac myocytes in laminopathies. The findings also point to the complexity of pathways involved in the pathogenesis of cardiac phenotypes in laminopathies. Hence, targeting of multiple pathways is expected to be required for therapeutic and preventive gains in this complex disorder.
Several measures were built into the study design to identify the primary transcriptomic changes and reduce the chance of fortuitous findings and the confounding factors. Transcriptomic changes were defined before and in the absence of discernible cardiac dysfunction, which enabled identification of dysregulated pathogenic pathways in the heart in laminopathies. Likewise, reversal of these molecular events along with partial phenotypic rescue supports the pathogenic role of FOXO TFs in induction of cardiac phenotype in laminopathies. To reduce the possibility of fortuitous effects, 2 control viral vectors, one expressing a scrambled shRNA and the other expressing the GFP protein but not an shRNA, were included as controls. To increase the transduction efficiency and hence garner robust data, recombinant AAV9 vectors were delivered in 3 sequential injections, with the last injection at P6. This approach is expected to transduce the newly formed cardiac myocytes, which occurs in the early postnatal days. 47 In addition, sequential injections during the early postnatal days was designed to avoid potential neutralizing effects of the antibodies against AAV9 capsids. Overall, the design of the study enabled garnering less confounded data.
The study has several shortcomings. The mechanism(s) responsible for doubling of the survival on knockdown of FOXO TFs is unclear. Whereas the number of apoptotic cells in the myocardium was significantly reduced, cardiac function, as assessed by echocardiography, was not improved. The presence of significant differences in BWs, major determinants of echocardiographic indices of cardiac size and function, among the experimental groups, hindered robust conclusions on the effects on cardiac function. In addition to heart failure, cardiac arrhythmias are also important causes of death in patients with laminopathies. 4, 5 Telemetric cardiac rhythm monitoring and electrophysiological studies were not performed in these mice, partly because of the small size of the Lmna −/− mice, to determine contributions of cardiac arrhythmias to premature death and improved survival in the experimental groups. It is also noteworthy that AAV9 constructs, despite their well-established tropism for cardiac myocytes, 54 ,55 also transduce skeletal muscles, including the diaphragm, and to a lesser extent the liver. 56, 57 Consequently, the survival benefit observed in the Lmna −/− mice on administration of AAV9-Foxo shRNA might be because of the effects of suppression of FOXO TF in other organs, such as the striated respiratory muscles, prevention of muscle atrophy, and the resultant improvement in respiratory efficiency, as shown in other models. 58, 59 The observed beneficial effects of suppression of FOXO TFs on survival and apoptosis are in agreement with the previous data showing deleterious effects of activation of FOXO3 in the heart but in apparent discord with its cardioprotective role, reported in the knock out studies. 60, 61 The key distinction, as opposed to the knock out studies, is that FOXO TFs were only partially suppressed and not totally abolished in our studies. Although excessive suppression, such as in genetic knock out studies, as well as excessive overexpression of FOXO TFs in the heart are expected to be deleterious, partial suppression of the already activated FOXO TFs is likely to beneficial. 62 The mechanistic basis of DETs and activation of FOXO TFs in the heart is unclear. Whether changes in the transcriptomics are the direct consequences of dysregulated LADs resulting from the deficiency of LMNA or are the consequences of impaired assembly of the other chromatin components to the LADs remain to be determined. Likewise, specific LADs in cardiac myocytes that are dysregulated in the absence of LMNA have yet-to-be identified. Therefore, direct data to show enrichment of LMNA and likewise, enrichment of the FOXO TFs on the promoter regions of their targets could not be demonstrated because of an inadequate quality of the available anti-LMNA and anti-FOXO antibodies for chromatin immunoprecipitation studies. Nevertheless, activation of FOXO1 and FOXO3 was confirmed at multiple levels, including their nuclear localization and reduced FOXO3 phosphorylation, as well as increased transcript levels of its target genes. Moreover, specific targeting of FOXO TFs by an shRNA, whose effectiveness has been shown in independent studies, 45, 46 in cardiac myocytes using AAV9 constructs partially rescued the molecular (gene expression), biological (apoptosis), and clinical (mortality) phenotypes. Collectively, these findings lend further support to the pathogenic activation of FOXO TFs in induction of cardiac phenotypes in laminopathies.
Analysis of RNA-Seq data shows activation of FOXO TFs in human heart failure with undefined mutations. Although preliminary and requiring testing for replication in additional samples and validation by complementary techniques, activation of FOXO TFs might be a general feature of heart failure and not specific to laminopathies. Consequently, one might speculate that FOXO TFs might be therapeutic targets in garden variety form of heart failure.
In conclusion, the findings implicate LMNA in the transcriptional regulation of several hundred genes and over a dozen upstream transcriptional regulators, including FOXO TFs in the heart. Dysregulations of these networks of TFs collectively, and FOXO1 and FOXO3 particularly, are in part responsible for induction of cardiac phenotype and early mortality in laminopathies. The findings identify FOXO TFs as potential targets to prevent or attenuate cardiac phenotype in laminopathies.
